Can You Take Provigil (Modafinil) with NSAIDs Like Ibuprofen or Naproxen?

How Modafinil and NSAIDs Interact at the Enzyme Level

Modafinil is both a substrate and a moderate inhibitor of cytochrome P450 2C9 (CYP2C9), one of the liver's busiest drug-metabolizing enzymes [1]. Ibuprofen's pharmacologically active S-enantiomer and naproxen both depend on CYP2C9 for oxidative clearance [2]. When modafinil occupies a portion of that enzyme's capacity, NSAID metabolism slows and circulating drug levels rise.

CYP2C9 Inhibition Potency

The modafinil FDA label classifies the drug as a "moderate" CYP2C9 inhibitor based on in-vitro microsomal data [1]. A 2002 pharmacokinetic study in healthy volunteers showed that modafinil 200 mg daily suppressed CYP2C9-mediated clearance of the probe substrate (S)-warfarin by roughly 17% [3]. That figure provides a reasonable proxy for the magnitude of NSAID AUC elevation, because warfarin and ibuprofen share the same metabolic pathway. Real-world impact at a single 400 mg ibuprofen dose is likely small. At chronic prescription-strength dosing (naproxen 500 mg twice daily), the accumulation effect becomes more relevant.

CYP2C19 and CYP3A4 Crosstalk

Modafinil also inhibits CYP2C19 and induces CYP3A4 [1]. Neither enzyme plays a major role in ibuprofen or naproxen clearance, so these secondary pathways do not meaningfully change the interaction profile. One exception: patients taking celecoxib (metabolized primarily by CYP2C9 with minor CYP3A4 contribution) could see a larger AUC increase than those on ibuprofen [4]. Celecoxib users on modafinil should discuss dose timing with their prescriber.

What the DDI Databases Say

Lexicomp and Micromedex rate the modafinil-ibuprofen pair as a "C" (monitor) interaction, not a "D" (consider modification) or "X" (avoid) [5]. The Clinical Pharmacology database concurs, noting theoretical but not clinically confirmed risk. No published case reports describe a serious adverse event from this specific pair.

GI Risk: Nausea, Ulceration, and Bleeding

Both modafinil and NSAIDs independently irritate the GI tract, so the combination deserves attention even without a dramatic enzyme-level clash.

Modafinil's GI Side-Effect Burden

In the key narcolepsy trials (pooled N=934), nausea occurred in 11% of modafinil-treated patients versus 3% on placebo [1]. Diarrhea hit 6% versus 3%. These rates come from the 200 mg and 400 mg arms combined. Anorexia, reported in 5%, may compound NSAID gastropathy risk by reducing the protective effect of food in the stomach.

NSAID Gastropathy Mechanisms

NSAIDs suppress cyclooxygenase-1 (COX-1) in gastric mucosa, cutting prostaglandin E2 production and weakening the mucosal barrier [6]. A meta-analysis of 18 RCTs (N=34,701) estimated that nonselective NSAIDs double the relative risk of upper GI complications (RR 2.0, 95% CI 1.8-2.2) [7]. Ibuprofen sits at the lower end of that risk spectrum; naproxen falls in the middle.

Combined GI Counseling

Patients taking modafinil who need an NSAID for more than 3 days should take the NSAID with food, consider a proton pump inhibitor (PPI) if they have a history of peptic ulcer disease, and report black or tarry stools immediately [6]. A short course of ibuprofen 200-400 mg for a headache is unlikely to cause mucosal damage in otherwise healthy adults.

Renal Considerations When Combining These Drugs

The kidney is the second organ system that warrants scrutiny. Neither drug is nephrotoxic in isolation at standard doses, but both can stress renal perfusion under specific conditions.

How NSAIDs Affect Renal Blood Flow

Prostaglandins produced by COX-2 in the afferent arteriole help maintain glomerular filtration rate (GFR) during states of reduced effective circulating volume [8]. NSAIDs block that compensatory vasodilation. The risk is highest in patients who are volume-depleted, on diuretics, or who have baseline chronic kidney disease (CKD) with an eGFR <60 mL/min/1.73 m² [8].

Modafinil's Renal Clearance Profile

Modafinil itself is <10% renally excreted as unchanged drug; the rest undergoes hepatic metabolism to modafinil acid and then renal elimination of the inactive metabolite [1]. Dose adjustment is not required until hepatic impairment (Child-Pugh B or C), per the FDA label. But modafinil can suppress thirst through its appetite-reducing and sympathomimetic-like properties. Patients who forget to drink water, especially shift workers relying on modafinil through overnight hours, enter a mild volume-depleted state that magnifies NSAID-related renal risk.

When to Check Labs

For a patient on daily modafinil who starts taking naproxen 500 mg twice daily for a musculoskeletal injury, the American College of Gastroenterology (ACG) and the AGA recommend checking serum creatinine and potassium at baseline and again at 7-14 days [9]. If eGFR drops by more than 20% from baseline, the NSAID should be stopped and reassessed.

Bleeding Risk and Anticoagulant Overlap

This section matters most for patients who also take warfarin, apixaban, or another anticoagulant alongside modafinil.

The Triple Overlap Problem

Modafinil inhibits CYP2C9, which metabolizes both S-warfarin and the NSAID. If a patient on warfarin adds ibuprofen while taking modafinil, three separate mechanisms push bleeding risk upward: (1) NSAID-mediated COX-1 inhibition impairs platelet aggregation, (2) modafinil raises NSAID levels through CYP2C9 inhibition, and (3) modafinil raises S-warfarin levels through the same enzyme [3]. The FDA label for modafinil specifically recommends more frequent INR monitoring in warfarin co-prescribed patients [1].

Guidance From the AHA

The American Heart Association's 2023 scientific statement on NSAID cardiovascular safety recommends avoiding NSAIDs in patients on dual antiplatelet therapy and limiting NSAID duration to <5 days when anticoagulants are present [10]. Adding modafinil to that picture does not change the recommendation but does add another reason to keep NSAID courses brief.

Dose and Timing Strategies to Minimize Risk

Practical dose management can reduce the interaction's clinical footprint to near zero for most patients.

Short-Course OTC Ibuprofen

For episodic pain (headache, dental pain, mild musculoskeletal strain), ibuprofen 200-400 mg taken with food, up to three times daily for no more than 3 days, poses minimal added risk on top of modafinil 100-200 mg [1][6]. No dose adjustment of either drug is needed.

Prescription-Strength Naproxen

Naproxen 500 mg twice daily for conditions like osteoarthritis or chronic low back pain requires a different calculus. The longer half-life of naproxen (12-17 hours versus 2-4 hours for ibuprofen) means the drug accumulates faster when clearance is impaired [2]. Spacing the modafinil dose (morning) from the first naproxen dose (with lunch) by at least 4 hours allows peak modafinil CYP2C9 occupancy to pass before the NSAID bolus hits the liver. This is a pharmacokinetic common-sense measure, not an evidence-based guideline, and it does not replace monitoring.

Alternative Analgesics

Acetaminophen (paracetamol) at doses up to 2 g/day bypasses the CYP2C9 interaction entirely and avoids COX-1-mediated GI and platelet effects [11]. For patients who need chronic pain management while on modafinil, acetaminophen is the lowest-risk first-line option. Topical NSAIDs (diclofenac gel) deliver <5% of the systemic exposure of oral formulations and represent another workaround when localized joint or muscle pain is the target [12].

Special Populations at Higher Risk

Adults Over 65

Age-related decline in CYP activity, reduced renal reserve, and higher baseline prevalence of GI erosive disease make older adults the most vulnerable group for this interaction [7]. The American Geriatrics Society Beers Criteria list chronic NSAID use as "potentially inappropriate" in adults 65 and older regardless of concurrent medications [13]. Modafinil adds a pharmacokinetic amplifier to that existing warning.

CKD Stage 2 and Beyond

Patients with eGFR between 30 and 89 mL/min/1.73 m² should avoid NSAIDs when possible. If an NSAID is clinically necessary, the prescriber should choose ibuprofen over naproxen (shorter half-life, faster washout) and monitor creatinine at days 3 and 7 [8].

CYP2C9 Poor Metabolizers

Approximately 1-3% of Caucasians and <1% of African Americans carry CYP2C9*3/*3 homozygous genotypes that reduce enzyme activity by over 90% [14]. These individuals already have elevated NSAID levels at standard doses. Adding modafinil's CYP2C9 inhibition on top of a genetically slow enzyme creates a compounding effect. Pharmacogenomic testing is not routinely ordered for NSAID prescriptions, but clinicians should suspect slow-metabolizer status in patients who report unusual NSAID sensitivity (easy bruising, GI upset at low doses).

What the FDA Labels Actually Say

The modafinil (Provigil) prescribing information devotes a full paragraph to CYP2C9 interactions, naming warfarin as the index drug and recommending INR monitoring [1]. It does not specifically name ibuprofen or naproxen. The ibuprofen label warns against combining with other drugs that affect renal prostaglandins but does not mention modafinil by name [6]. The naproxen label carries identical language [2].

This gap is common in drug labeling. The FDA requires interaction warnings for drugs studied in formal PK trials. No dedicated modafinil-ibuprofen or modafinil-naproxen PK trial has been published. The interaction is inferred from the shared CYP2C9 pathway and the warfarin interaction data, which is standard pharmacological reasoning accepted by clinical pharmacology consensus [15].

Monitoring Checklist for Clinicians

A concise monitoring protocol for patients on modafinil 100-400 mg daily who start NSAID therapy:

• Day 0 (before NSAID start): baseline serum creatinine, eGFR, CBC with differential, and stool guaiac if the patient has GI risk factors.
• Day 7-14: repeat creatinine and eGFR. If eGFR drops more than 20%, discontinue the NSAID.
• Day 30 (if NSAID continues): repeat CBC, creatinine, and hepatic panel. Reassess clinical need for the NSAID.
• Ongoing: counsel patient on hydration (minimum 2 L/day unless fluid-restricted), signs of GI bleeding, and symptoms of acute kidney injury (reduced urine output, peripheral edema, fatigue).

This protocol applies to prescription-strength or chronic OTC NSAID use. A single dose of ibuprofen 200 mg for a headache does not require lab work.